We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nasal Microbiome Influences Pneumonia and Related Diseases

By LabMedica International staff writers
Posted on 15 Jul 2019
Image: Digitally colorized photomicrograph of fluorescent antibody labeled Streptococcus pneumoniae bacteria in spinal fluid sample (Photo courtesy of the CDC).
Image: Digitally colorized photomicrograph of fluorescent antibody labeled Streptococcus pneumoniae bacteria in spinal fluid sample (Photo courtesy of the CDC).
A recent study examined the influence of the natural microbial flora in the nose and viral co-infection on the acquisition of Streptococcus pneumoniae bacteria and the development of pneumococcal diseases.

S. pneumoniae is the main bacterial pathogen involved in pneumonia. It has been speculated that acquisition of the bacteria and colonization density was probably affected by viral co-infections, the local microbiome composition, and mucosal immunity. To examine the relationship between the nasal microbiome and acquisition of S. pneumoniae bacteria, investigators at Liverpool School of Tropical Medicine (United Kingdom) and the University of Edinburgh (United Kingdom) used an experimental human challenge model (the Experimental Human Pneumococcal Challenge) and inoculated live bacteria in combination with a live virus in the form of the readily available nasal vaccine for influenza.

Working with this model, the investigators examined the interactions between live-attenuated influenza vaccine (LAIV), successive pneumococcal challenge, and the healthy adult nasal microbiota and mucosal immunity.

Results indicated that the equilibrium between the nasal microbiome and the host immune system had an impact on pneumococcal acquisition and density, in particular when combined with a viral co-infection. The microbial flora in the nose also appeared to have an effect on replication of the pathogenic virus itself.

Contributing author Dr. Daniela Ferreira, professor of respiratory vaccines and infection immunology at Liverpool School of Tropical Medicine, said, "We knew relatively little about the relationship between viral infections and the microbiota. Our model helped us to establish a link between baseline microbiota and colonization with the bacteria which causes pneumonia and shows the way that it is apparently altered with the introduction of a viral pathogen."

Senior author Dr. Debby Bogaert, professor of inflammation research at the University of Edinburgh, said, "Using this sophisticated human challenge model, we were for the first time able to identify that different constellations of microbes in the nose are associated with more or less inflammation, viral replication, and pneumococcal carriage receptiveness."

The work was published in the July 5, 2019, online edition of the journal Nature Communications.

Related Links:
Liverpool School of Tropical Medicine
University of Edinburgh

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Pipette
Accumax Smart Series

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more